MedTrace Logo

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

NCT02724917 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-07-13

No results posted yet for this study

Summary

The purpose of this study in patients with schizophrenia is to evaluate the safety, tolerability, and pharmacokinetics of 3 doses (low, mid, high) of APN1125 compared with placebo when administered as repeated daily oral doses.

Conditions

Interventions

DRUG

APN1125

Oral solid dose form of APN1125

DRUG

Placebo

Placebo to match

Sponsors & Collaborators

  • Alpharmagen, Inc.

    collaborator INDUSTRY

  • CoMentis

    lead INDUSTRY

Principal Investigators

  • David P Walling, PhD · Collaborative Neuroscience Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-09-30
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02724917 on ClinicalTrials.gov